MedTrace Logo

Impact of Dialysis Modality

NCT07479888 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2026-03-18

No results posted yet for this study

Summary

* Peripheral Arterial Disease (PAD) is a common condition in patients with End-Stage Renal Failure (ESRF) undergoing dialysis.
* Late diagnosis of PAD and hypoperfusion induced by dialysis sessions explain the high morbidity and mortality associated with this condition in hemodialysis patients compared to the general population.
* The main objective of this study is to evaluate whether a dialysis modality (conventional 4-hour sessions 3 times per week or daily 2-hour sessions 6 times per week) is more effective in preventing the progression of critical limb ischemia during dialysis and thus preventing serious complications of PAD.

This study will help define a population of chronic hemodialysis patients at risk of developing critical limb ischemia during dialysis sessions. This will allow us to offer them the dialysis modality that best maintains distal perfusion of the lower limbs and may prevent the onset of trophic disorders.

Conditions

  • Dialysis

Interventions

DIAGNOSTIC_TEST

Evaluation of the occurrence of critical lower limb ischemia during dialysis in patients undergoing chronic hemodialysis

It will be assessed whether a dialysis modality (conventional 4-hour session 3 times a week or daily 2-hour session 6 times a week) allows for greater prevention of perialysis of the lower limbs in critical ischemia defined by a pressure at the big toe \< 30 mmHg or 50 mmHg in the presence of trophic disorders

Sponsors & Collaborators

  • University Hospital, Rouen

    lead OTHER

Principal Investigators

  • Mélanie MH HANOY, Doctor · University Rouen Hospiotal, Service de Néphrologie

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-06
Primary Completion
2024-06-02
Completion
2025-06-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07479888 on ClinicalTrials.gov